Evidence map›Paper›PMID 38699801›Full record

Trial reportPediatrics2024

Advance Care Planning for Children With Rare Diseases: A Pilot RCT.

Maureen E Lyon, Jamie L Fraser, Jessica D Thompkins, Heidi Clark, Nicola Brodie, Kathryn Detwiler, Clarivet Torres, Michael F Guerrera, Tamiko Younge, Samar Aoun and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06548022 (Rare Group Problem Management Plus), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06548022 nacompletednot on this map

Rare Group Problem Management Plus

TypeinterventionalSponsorChildren's National Research InstituteRan2024 to 2025Enrolled8ConditionsAnxiety, Depressive Symptoms, Post-traumatic Stress Disorder, Problems PsychosocialArmsRare Group Problem Management Plus
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. "The American journal of hospice & palliative care · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maureen E LyonChildren's National Hospital, Washington, District of Columbia.
Jamie L FraserChildren's National Hospital, Washington, District of Columbia.
Jessica D ThompkinsChildren's National Hospital, Washington, District of Columbia.
Heidi ClarkChildren's National Hospital, Washington, District of Columbia.
Nicola BrodieChildren's National Hospital, Washington, District of Columbia.
Kathryn DetwilerChildren's National Hospital, Washington, District of Columbia.
Clarivet TorresChildren's National Hospital, Washington, District of Columbia.
Michael F GuerreraChildren's National Hospital, Washington, District of Columbia.
Tamiko YoungeChildren's National Hospital, Washington, District of Columbia.
Samar AounPeron Institute, Palliative Care, The Western University of Australia, Perth, Washington, Australia.
Eduardo A Trujillo RiveraChildren's National Hospital, Washington, District of Columbia.

Funding

Clinical and Translational Science Institute at Children's NationalUL1TR000075 · NCATS · CHILDREN'S RESEARCH INSTITUTE · PI GUAY-WOODFORD, LISA MARIE · 2012 to 2015
$13.7M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR031988 · NCRR · CHILDREN'S RESEARCH INSTITUTE · PI GUAY-WOODFORD, LISA MARIE · 2010 to 2011
$8.2M
Palliative Care Needs of Children with Rare Diseases and their FamiliesR21NR019340 · NINR · CHILDREN'S RESEARCH INSTITUTE · PI LYON, MAUREEN ELLEN · 2020 to 2021
$491k
NCATS NIH HHS UL1 TR000075NCRR NIH HHS UL1 RR031988NINR NIH HHS R21 NR019340
6 · The paper itself

Abstract

BACKGROUND AND

objectivePediatric rare diseases are often life-limiting conditions and/or require constant caregiving. Investigators assessed the initial efficacy of the FAmily CEntered (FACE) pediatric advance care planning (pACP), FACE-Rare, intervention on families' quality of life.

methodsA pilot-phase, single-blinded, intent-to-treat, randomized controlled clinical trial enrolled families from 1 pediatric quaternary hospital between 2021 and 2023. Intervention families received 3 weekly 60-minute (FACE-Rare pACP) sessions: (1) Carer Support Needs Assessment Tool or Action Plan, (2) Carer Support Needs Assessment Tol Action Plan Review, and (3) Pediatric Next Steps: Respecting Choices pACP. Controls received treatment as usual (TAU). Outcome measures were Beck Anxiety Inventory, Family Appraisal of Caregiving, Functional Assessment of Chronic Illness Therapy (FACIT)-Spirituality, and health care utilization. Generalized mixed effect models with γ response assessed the intervention effect at 3-month follow-up.

resultsChildren (n = 21) were aged 1 to 10 years, 48% male, 24% Black; and 100% technology dependent. Primary family caregivers (n = 21) were aged 30 to 43 years, 19% male, 19% Black; and 27% household income below the Federal poverty level. Dyads underwent 1:1 randomization: 9 to FACE-Rare and 12 to TAU. TAU caregivers reported statistically lower meaning and peace than FACE-Rare caregivers (0.9, P = .03, confidence interval [CI]: 0.75-0.99). Black caregivers reported significantly less caregiver distress (0.7, P = .04, CI: 0.47-0.98) than non-Black caregivers. Poor families reported more anxiety (3.5, P = .002, CI: 1.62-7.94), more caregiver strain (1.2, P = .006, CI: 1.07-1.42); and less family well-being (0.8, P = .02, CI: 0.64-0.95).

conclusionsFACE®-Rare was feasible, acceptable, safe, and demonstrated initial efficacy, providing greater feelings of meaning and peace to caregivers. Poverty impacted well-being. A multisite trial is needed to determine generalizability.

Indexed as

Advance Care PlanningCaregiversQuality of LifeRare DiseasesAdultChildChild, PreschoolFemaleHumansInfantMaleNeeds AssessmentPilot ProjectsSingle-Blind Method

Identifiers

PMID38699801
PMCPMC11153326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.